Tamtam Try Tamtam free
Organon logo

Organon account plan

Healthcare therapies and products

At a glance

Organon is a global healthcare company in women's health and general medicines with FY2025 revenues of $6,216 million, being acquired by Sun Pharma.

Organon & Co., spun off from Merck in 2021 and headquartered in Jersey City, New Jersey, sells a portfolio of over 70 products across women's health and general medicines (biosimilars and established brands) in over 140 countries and territories. FY2025 revenues were $6,216 million, down 3%, with approximately 74% generated outside the United States; net income was $187 million and adjusted EBITDA $1.9 billion. It had over 10,000 employees at year-end 2025 and six owned plants in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the UK. On April 26, 2026 it agreed to be acquired by Sun Pharma for $14.00 per share in cash, with closing expected by early 2027.

Business units

Strategic priorities

Deleveraging
Reduce net leverage from approximately 4.3x at end-2025 to below 4 times by the end of 2026, with the dividend cut to $0.02 per quarter, the Jada divestiture and debt repurchases.
Cost savings
Over $200 million in cost savings in 2025, and another round of opex savings built into 2026 guidance.
Revenue growth from newer products
Volume growth of about $150 million in 2026 from Vtama (expected to grow 20-25%), Emgality, biosimilars and Nexplanon outside the US.
Late-stage business development
Favour later-stage or marketed women's health assets, such as the Miudella hormone-free copper IUD licensed from Sebela, over early-stage R&D.
Manufacturing separation from Merck
Exit supply agreements with Merck through 2031, which should support gross margin expansion from 2027.
Close the Sun Pharma acquisition
Stockholders approved the $14.00 per share cash deal on July 23, 2026; regulatory approvals are pending, with closing expected by early 2027.

Latest results

In Q3 2026 (quarter ended September 30) sales were $1,574 million, down 2% (down 3% ex-FX), with US sales $411 million (+1%) and International $1,163 million (-3%). Net income was $164 million against $160 million a year earlier, and interest expense fell 17% to $106 million. Nexplanon fell 10% while Hadlima, Vtama and Emgality grew; supply constraints cut revenue by less than 2%. Nine-month sales were $4,592 million (down 2%), and cash rose to $1.46 billion. FY2026 guidance given in February 2026 was about $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA.

Investments and deals

Jada divestiture
Sold to Laborie in January 2026 for up to $465 million ($440 million plus up to $25 million earnout), with net proceeds of approximately $390 million used to reduce debt.
Miudella licence
February 19, 2026 exclusive global licence from Sebela for a hormone-free copper IUD; $27.5 million paid in June 2026, with sales milestones up to $505 million and US launch estimated in late 2026.
Biosimilar portfolio changes
Tofidence US rights acquired from Biogen in March 2025, and Samsung Bioepis amendments adding Pyzchiva in Canada and Epyztek in Australia while returning Ontruzant and Aybintio rights in some markets.
Oss Biotech site
Fertility drug substance plant purchased from Merck in July 2025 ($25 million plus $71 million of inventory).

Challenges and risks

High debt
Debt obligations of $8.7 billion through 2034, with approximately $3.6 billion of notes maturing in 2028, and interest expense of $504 million in 2025.
Nexplanon pressure
US policy restrictions at Planned Parenthood and federally qualified health centres, fewer reinsertions with the five-year label, and US rod patents expiring in 2027.
Loss of exclusivity and price erosion
LOE reduced 2025 sales by approximately $197 million, China volume-based procurement weighs on general medicines, and US drug-pricing reform adds pressure.
Governance and controls
An Audit Committee investigation found Nexplanon sales pushed to two US wholesalers, leading to material weaknesses, an Interim CEO and a $301 million goodwill impairment on the US unit in 2025.
Supply constraints
Disruptions at a key contract manufacturer, a third-party logistics provider and geopolitical events constrained Established Brands revenue in 2026; several materials are sole-sourced.

What leadership says

“In 2025, Organon delivered $6.2 billion in revenue and $1.9 billion of adjusted EBITDA.”

Joseph Morrissey, Interim CEO · Q4 and full-year 2025 earnings call, February 12, 2026

“deleveraging the business, driving cost savings and achieving revenue growth.”

Joseph Morrissey, Interim CEO · On his priorities, Q3 2025 earnings call, November 10, 2025

“we don't see any strategic changes.”

Carrie Cox, Executive Chair · Q3 2025 earnings call, November 10, 2025

“net leverage below 4 times by the end of the year”

Matthew Walsh, CFO · Q4 and full-year 2025 earnings call, February 12, 2026

Where a supplier can help

Supply chain resilience
Tied to the supply constraints challenge and the Merck manufacturing separation: contract manufacturing, logistics and supplier diversification services.
Cost reduction and integration
Tied to the cost savings priority and the pending Sun Pharma acquisition: operating efficiency and integration support ahead of closing.
Compliance and commercial controls
Tied to the governance challenge: sales controls, training and disclosure tooling that support remediation of the material weaknesses.
Omnichannel commercial support for launches
Tied to the revenue growth priority: digital and field engagement tools for Vtama international launches, Miudella and biosimilars, run by about 4,000 commercialization staff.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Organon?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Organon

What does Organon do?

Organon is a global healthcare company with over 70 products in women's health (contraception, fertility), biosimilars and established brands, sold in over 140 countries and territories.

What is Organon's revenue?

FY2025 revenues were $6,216 million, down 3%, with about $1.9 billion of adjusted EBITDA. Q3 2026 sales were $1,574 million.

How many employees does Organon have?

Organon had over 10,000 employees at year-end 2025, approximately 1,500 of them in the United States.

Who leads Organon?

Joseph Morrissey has been Interim CEO since October 27, 2025, with Carrie S. Cox as Executive Chair and Matthew Walsh as CFO.

Is Organon being acquired?

Yes. Sun Pharma agreed on April 26, 2026 to acquire Organon for $14.00 per share in cash; stockholders approved it on July 23, 2026, and closing is expected by early 2027.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)